ZENITH
KEEPING HOPES ALIVE

ZENITH DRUGS LIMITED
(Formerly - Zenith Drugs Private Limited)
CONTACT US:
www.zenithdrugs.com
info@zenithdrugs.com
+91 93291 45074 CIN: L24231MP2000PLC014465
Plant Add.- 72/5 & 72/1, 72/3, 74/1/1, 75/1/1 Muradpura (Orangpura), Dhar Road, Near Kalaria, INDORE, PIN-453001 (MP) INDIA

Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

Date: June 26, 2026

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051, Maharashtra, India.

NSE Symbol: ZENITHDRUG; ISIN- INE0QWN01013

Sub: Outcome of Meeting of Board of Directors held on June 26, 2026.

Dear Sir/Ma'am,

We would like to inform you that the Board of Directors in its meeting held today i.e. on Friday, June 26, 2026, has inter alia considered and approved the following businesses:

1. Raising of funds through issuance and allotment of up to 16,09,050 (Sixteen Lakh Nine Thousand Fifty) warrants, each Warrant convertible into 1 (one) Equity Share of the Face Value of Rs. 10/- (Rupees Ten Only) to certain Promoter Investors (as per 'Annexure B') on preferential basis in terms of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") at an issue Price of Rs. 43.50/- (Rupees Forty Three and Fifty paisa Only) including premium of Rs. 33.50/- (Rupees Thirty Three and Fifty paisa Only) per warrant (being the price not less than the minimum price determined with reference to the Relevant Date in accordance with Regulation 164 of the ICDR Regulations) aggregating up to maximum amount of Rs. 6,99,93,675/- [Rupees Six Crore Ninety Nine Lakh Ninety Three Thousand Six Hundred Seventy Five Only], subject to the approval of regulatory/ statutory authorities and the Members of the Company at ensuing Extra Ordinary General Meeting.

   The Relevant Date in terms of SEBI ICDR Regulations is Tuesday, 23rd June, 2026.

2. The Board of Directors have appointed Mr. Shubham Jain, Partner at G&J Associates, Practicing Company Secretaries Firm, as the Scrutinizer for scrutinizing the E-Voting process for the Extra Ordinary General Meeting of the Company as per the provisions of Companies Act, 2013 and other applicable provisions, if any, and rules made there under.

3. Convening of Extra-Ordinary General Meeting (EGM) of the shareholders of the Company on Thursday, 23rd July, 2026 at 02:00 PM, through video conferencing or other audio-visual means, for seeking necessary approval of the Members for the aforesaid matter.

Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure A and Annexure B**.

The Board meeting commenced at 05:30 P.M. and concluded at 06:12 P.M.

Thanking you
Yours faithfully

For Zenith Drugs Limited

SAKSHI
BHAWSAR

SAKSHI BHAWSAR
Company Secretary and Compliance Officer

ANNEXURE A

The details as required to be disclosed under Regulation 30 read with SEBI Circular dated January 30, 2026:

Sr. No	Particulars	Details
1	Type of securities proposed to be issued (viz. equity shares, convertibles, etc.	Warrants convertible into Equity Shares of Rs. 10/- each, i.e., 1 equity share for 1 warrant
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential Issue on private placement basis
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Issue of Up to 16,09,050 (Sixteen Lakh Nine Thousand Fifty Only) Convertible Warrants into equity shares Issue of up to 16,09,050 (Sixteen Lakh Nine Thousand Fifty Only) Warrants at a price of Rs. 43.50/- (Rupees Forty-Three and Fifty paisa Only) per Warrant, each convertible into 1 (one) Equity Share of face value of Rs. 10/- (Rupees Ten Only) each fully paid up at a premium of Rs. 33.50/- (Rupees Thirty-Three and Fifty paisa Only) each per warrant ("Issue Price") in cash, for an aggregate consideration of up to Rs. 6,99,93,675/- (Rupees Six Crores Ninety Nine Lakhs Ninety Three Thousand Six Hundred and Seventy Five Only)
In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):		
A	Number of Proposed Allottee(s)	3 (Three)
B	Names of the Proposed Allotee(s)	***As per Annexure B as below***
C	Issue price for preferential allotment	Rs. 43.50/- per warrant including premium of Rs. 33.50/- (Rupees Thirty Three and Fifty paisa Only)
D	Post allotment of securities- outcome of the subscription, issue price allotted price (in case of convertibles), number of investors	The details of securities, prior to and after the proposed preferential allotment, are as under: "***Please refer Annexure B below***"
E	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	The warrant holders are, subject to the SEBI (ICDR) Regulations and other applicable rules, regulations and laws, entitled to exercise the warrants in one and more tranches within a period of 18 months from the date of allotment of the warrant by issuing a written notice to the company specifying the number of warrants proposed to be exercise. The Company shall accordingly issue and allot the corresponding number of equity shares of face value of Rs. 10/- each to the warrants holders; An amount equivalent to 25% of the warrant issue price to be received at the time of subscription and allotment of each warrants and the balance 75% shall be payable by the warrants holder(s) on exercise of warrant(s); In the event that, a warrant holder does not exercise the warrants within a period of 18 months from the date of allotment of such warrants, the unexercised warrants shall lapse and the amount paid by the warrants holders on such warrants shall stand forfeited by the Company
F	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable

Annexure B

Sr. No.	Name of the Proposed Allottee	No. of Convertible warrant into equity share (upto)	Category	Pre-preferential Issue Shareholding Percentage of the proposed allottees	% of Pre Issue Holding	*Post preferential Issue Shareholding of the proposed allottees	% of Post Issue Holding
1	AJAY SINGH DASSUNDI	5,36,350	Promoter	38,61,990	22.52%	43,98,340	23.44%
2	SANDEEP BHARDWAJ	5,36,350	Promoter	36,66,990	21.38%	42,03,340	22.40%
3	BHUPESH SONI	5,36,350	Promoter	34,60,980	20.18%	39,97,330	21.34%
	Total	**16,09,050**		**1,09,89,960**	**64.08%**	**1,25,99,010**	**67.18%**

* The above mentioned post preferential issue shareholding pattern of the Company is calculated on basis of assuming full subscription of convertible warrants into equity share to be allotted under the present issue.